[1] Crabb, David W et al. Diagnosis and Treatment of Alcohol‐Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases. Hepatology 71(1):p 306-333, January 2020
[2] Eslam, Mohammed, et al. "The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease." Hepatology international 14 (2020): 889-919.
[1] Crabb, David W et al. Diagnosis and Treatment of Alcohol‐Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases. Hepatology 71(1):p 306-333, January 2020
[2] Eslam, Mohammed, et al. "The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease." Hepatology international 14 (2020): 889-919.
[3] Kneeman, Jacob M et al. "Secondary causes of nonalcoholic fatty liver disease." Therapeutic advances in gastroenterology 5.3 (2012): 199-207.
[4] Joy, Diamond et al. "Diagnosis of fatty liver disease: is biopsy necessary?." European journal of gastroenterology & hepatology 15.5 (2003): 539-543.
[5] Nevola, Riccardo, et al. "GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives." International Journal of Molecular Sciences 24.2 (2023): 1703.
[6] Volpe S, et al. Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study. Nutrients. 2022 Nov 4;14(21):4673.
[7] Silverman, Eugene M et al. "Regression of hepatic steatosis in morbidly obese persons after gastric bypass." American journal of clinical pathology 104.1 (1995): 23-31.
[8] Hafeez, Shuja et al. "Bariatric surgery as potential treatment for nonalcoholic fatty liver disease: a future treatment by choice or by chance?." Journal of obesity 2013.1 (2013): 839275.
[9] Mattar, Samer G., et al. "Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome." Annals of surgery 242.4 (2005): 610-620.
[10] Dulai, Parambir S et al. "Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta‐analysis." Hepatology 65.5 (2017): 1557-1565.
Armstrong, Matthew James, et al. "Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study." The Lancet 387.10019 (2016): 679-690.
Belfort, Renata, et al. "A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis." New England Journal of Medicine 355.22 (2006): 2297-2307.
Klein, Eric A., et al. "Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)." Jama 306.14 (2011): 1549-1556.
Loh, Wei Qi, Jiyoung Youn, and Wei Jie Seow. "Vitamin E intake and risk of prostate cancer: A meta-analysis." Nutrients 15.1 (2022): 14.
